Suppr超能文献

补体成分 C3 与活化的正常血小板结合,而无需先前的蛋白水解激活,并促进与补体受体 1 的结合。

Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1.

机构信息

Division of Clinical Immunology, Rudbeck Laboratory C5, Uppsala University, Uppsala, Sweden.

出版信息

J Immunol. 2010 Mar 1;184(5):2686-92. doi: 10.4049/jimmunol.0902810. Epub 2010 Feb 5.

Abstract

It has been reported that complement is activated on the surface of activated platelets, despite the presence of multiple regulators of complement activation. To reinvestigate the mechanisms by which activated platelets bind to complement components, the presence of complement proteins on the surfaces of nonactivated and thrombin receptor-activating peptide-activated platelets was analyzed by flow cytometry and Western blot analyses. C1q, C4, C3, and C9 were found to bind to thrombin receptor-activating peptide-activated platelets in lepirudin-anticoagulated platelet-rich plasma (PRP) and whole blood. However, inhibiting complement activation at the C1q or C3 level did not block the binding of C3 to activated platelets. Diluting PRP and chelating divalent cations also had no effect, further indicating that the deposition of complement components was independent of complement activation. Furthermore, washed, activated platelets bound added C1q and C3 to the same extent as platelets in PRP. The use of mAbs against different forms of C3 demonstrated that the bound C3 consisted of C3(H(2)O). Furthermore, exogenously added soluble complement receptor 1 was shown to bind to this form of platelet-bound C3. These observations indicate that there is no complement activation on the surface of platelets under physiological conditions. This situation is in direct contrast to a number of pathological conditions in which regulators of complement activation are lacking and thrombocytopenia and thrombotic disease are the ultimate result. However, the generation of C3(H(2)O) represents nonproteolytic activation of C3 and after factor I cleavage may act as a ligand for receptor binding.

摘要

据报道,尽管存在多种补体激活的调节因子,但补体在活化血小板表面被激活。为了重新研究活化血小板与补体成分结合的机制,通过流式细胞术和 Western blot 分析,分析了非活化和凝血酶受体激活肽活化血小板表面补体蛋白的存在。在 lepirudin 抗凝的富含血小板血浆(PRP)和全血中,发现 C1q、C4、C3 和 C9 与凝血酶受体激活肽活化的血小板结合。然而,在 C1q 或 C3 水平抑制补体激活并不能阻止 C3 与活化血小板的结合。稀释 PRP 和螯合二价阳离子也没有效果,进一步表明补体成分的沉积不依赖于补体激活。此外,洗涤后的活化血小板与 PRP 中的血小板结合相同量的添加的 C1q 和 C3。使用针对不同形式的 C3 的 mAb 表明,结合的 C3 由 C3(H(2)O)组成。此外,外源性添加的可溶性补体受体 1 被证明与这种形式的血小板结合的 C3 结合。这些观察表明,在生理条件下,血小板表面没有补体激活。这种情况与许多病理条件形成鲜明对比,在这些病理条件下,缺乏补体激活的调节因子,最终导致血小板减少症和血栓性疾病。然而,C3(H(2)O)的产生代表 C3 的非蛋白水解激活,并且在因子 I 切割后可能作为受体结合的配体起作用。

相似文献

3
Blood platelets activate the classical pathway of human complement.血小板激活人类补体的经典途径。
J Thromb Haemost. 2006 Sep;4(9):2035-42. doi: 10.1111/j.1538-7836.2006.02065.x.

引用本文的文献

1
Platelets in infection: intrinsic roles and functional outcomes.感染中的血小板:内在作用与功能结果
Front Immunol. 2025 Jul 7;16:1616783. doi: 10.3389/fimmu.2025.1616783. eCollection 2025.
4
Immunity and Coagulation in COVID-19.新型冠状病毒肺炎中的免疫与凝血。
Int J Mol Sci. 2024 Oct 19;25(20):11267. doi: 10.3390/ijms252011267.
5
Activation of platelets and the complement system in mice with -induced pulmonary hypertension.诱导的肺动脉高压小鼠中血小板和补体系统的激活。
Am J Physiol Lung Cell Mol Physiol. 2024 Nov 1;327(5):L661-L668. doi: 10.1152/ajplung.00165.2024. Epub 2024 Sep 10.

本文引用的文献

5
Blood platelets activate the classical pathway of human complement.血小板激活人类补体的经典途径。
J Thromb Haemost. 2006 Sep;4(9):2035-42. doi: 10.1111/j.1538-7836.2006.02065.x.
8
Platelets in sepsis.脓毒症中的血小板
Hematology. 2005;10 Suppl 1:129-31. doi: 10.1080/10245330512331390177.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验